Contributors
JJ
TW, JZ, and NX made the development plan of the vaccine, designed the study protocol, and monitored the trial. FZ was the global principal investigator of this trial. AMJ, THD, JGP, AGD, LST, GMAZ, REMV, GPG, LLGB, and SPIP were the principal investigator of each site and managed the participants. SH, XL, QC, CZ, JH, JT, KZ, JQ, HL, JJ, and XC supervised the trial. FZ, SH, XL, QC, CZ, YS, TW, JZ, and NX have accessed and verified all the data in the study. QC, CZ, YS, TW, and JZ did the statistical analysis. HZ, JH, JC, YC, CL, and XY provided consultation for the investigational product. CZ, YH, TZ, and TW drafted the manuscript; TW, JZ, and NX reviewed the manuscript. All authors read and approved the final version of the manuscript for submission. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.